Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 28, 2017; 23(16): 2978-2986
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2978
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2978
Table 5 Treatment efficacies of various antiviral therapies
| Virological parameter at 96 wk | LAM + ADV | Telbivudine | Entecavir tablets | Entecavir dispersible tablets | P value |
| HBV DNA below detection (< 1000 IU/mL as a reference) | 68.75% | 66.67% | 79.66% | 78.13% | 0.089 |
| ALT normalization rate | 81.25% | 75.76% | 86.44% | 85.94% | 0.096 |
| Rate of conversion to HBeAg negative status | 31.25% | 36.36% | 35.59% | 34.38% | 0.615 |
| HBeAg seroconversion rate | 25.00% | 33.33% | 32.20% | 31.25% | 0.203 |
- Citation: Fu XY, Tan DM, Liu CM, Gu B, Hu LH, Peng ZT, Chen B, Xie YL, Gong HY, Hu XX, Yao LH, Xu XP, Fu ZY, He LQ, Li SH, Long YZ, Li DH, Gu JL, Peng SF. Early hepatitis B viral DNA clearance predicts treatment response at week 96. World J Gastroenterol 2017; 23(16): 2978-2986
- URL: https://www.wjgnet.com/1007-9327/full/v23/i16/2978.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i16.2978